Dow Down0.00% Nasdaq Up0.48%

Organovo Holdings, Inc. (ONVO)

-NYSE MKT
6.45 Down 0.05(0.72%) 1:51PM EST - Nasdaq Real Time Price
ProfileGet Profile for:
Organovo Holdings, Inc.
6275 Nancy Ridge Drive
Suite 110
San Diego, CA 92121
United States - Map
Phone: 858-550-9994
Website: http://www.organovo.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Medical Laboratories & Research
Full Time Employees:60

Business Summary 

Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L’Oreal. The company was founded in 2007 and is headquartered in San Diego, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Organovo Holdings, Inc.

Corporate Governance 
Organovo Holdings, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 6; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Keith Murphy , 42
Chairman, Chief Exec. Officer, Pres, Member of Audit Committee and Member of Science & Technology Committee
490.00K0.00
Mr. Barry D. Michaels , 64
Chief Financial Officer, Principal Accounting Officer and Sec.
391.00K497.00K
Dr. Sharon Collins Presnell Ph.D., 45
Chief Technology Officer and Exec. VP of R&D
379.00K0.00
Mr. Michael Renard , 55
Exec. VP of Commercial Operations
359.00K394.00K
Dr. Eric Michael David M.D., J.D., Ph.D., 42
Chief Strategy Officer
371.00K0.00
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders